{
    "id": 27014,
    "fullName": "RAD51C R193L",
    "impact": "missense",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "RAD51C R193L does not lie within any known functional domains of the Rad51c protein (UniProt.org). R193L, described as a reversion mutation, has no effect on Rad51c protein function, as demonstrated by restoration of homologous recombination function similar to wild-type Rad51c in cultured cells, and is associated with acquired resistance to PARP inhibitors (PMID: 28588062).",
            "references": [
                {
                    "id": 9883,
                    "pubMedId": 28588062,
                    "title": "Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28588062"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 5889,
        "geneSymbol": "RAD51C",
        "terms": [
            "RAD51C",
            "BROVCA3",
            "FANCO",
            "R51H3",
            "RAD51L2"
        ]
    },
    "variant": "R193L",
    "createDate": "09/25/2017",
    "updateDate": "06/30/2018",
    "referenceTranscriptCoordinates": {
        "id": 116058,
        "transcript": "NM_058216",
        "gDna": "chr17:g.58703202G>T",
        "cDna": "c.578G>T",
        "protein": "p.R193L",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 12044,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ovarian carcinoma cells expressing RAD51C R193L demonstrated resistance to Talazoparib (BMN-673) in culture (PMID: 28588062).",
            "molecularProfile": {
                "id": 28390,
                "profileName": "RAD51C R193L"
            },
            "therapy": {
                "id": 682,
                "therapyName": "Talazoparib",
                "synonyms": null
            },
            "indication": {
                "id": 4001,
                "name": "ovarian carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9883,
                    "pubMedId": 28588062,
                    "title": "Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28588062"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12035,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ovarian carcinoma cells expressing RAD51C R193L demonstrated resistance to Rubraca (rucaparib) in culture (PMID: 28588062).",
            "molecularProfile": {
                "id": 28390,
                "profileName": "RAD51C R193L"
            },
            "therapy": {
                "id": 906,
                "therapyName": "Rucaparib",
                "synonyms": null
            },
            "indication": {
                "id": 4001,
                "name": "ovarian carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9883,
                    "pubMedId": 28588062,
                    "title": "Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28588062"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12038,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ovarian carcinoma cells expressing RAD51C R193L demonstrated resistance to Zejula (niraparib) in culture (PMID: 28588062).",
            "molecularProfile": {
                "id": 28390,
                "profileName": "RAD51C R193L"
            },
            "therapy": {
                "id": 832,
                "therapyName": "Niraparib",
                "synonyms": null
            },
            "indication": {
                "id": 4001,
                "name": "ovarian carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9883,
                    "pubMedId": 28588062,
                    "title": "Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28588062"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12041,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ovarian carcinoma cells expressing RAD51C R193L demonstrated resistance to Lynparza (olaparib) in culture (PMID: 28588062).",
            "molecularProfile": {
                "id": 28390,
                "profileName": "RAD51C R193L"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 4001,
                "name": "ovarian carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9883,
                    "pubMedId": 28588062,
                    "title": "Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28588062"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12033,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, an ovarian carcinoma patient harboring a RAD51C R193* germline mutation developed resistance to Rubraca (rucaparib) after acquisition of RAD51C R193W, RAD51C H192_R193delinsGG, and RAD51C R193L (PMID: 28588062).",
            "molecularProfile": {
                "id": 28392,
                "profileName": "RAD51C H192_R193delinsGG RAD51C R193* RAD51C R193L RAD51C R193W"
            },
            "therapy": {
                "id": 906,
                "therapyName": "Rucaparib",
                "synonyms": null
            },
            "indication": {
                "id": 4001,
                "name": "ovarian carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 9883,
                    "pubMedId": 28588062,
                    "title": "Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28588062"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 28390,
            "profileName": "RAD51C R193L",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28392,
            "profileName": "RAD51C H192_R193delinsGG RAD51C R193* RAD51C R193L RAD51C R193W",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 116060,
            "transcript": "XM_006722002",
            "gDna": "chr17:g.58703202G>T",
            "cDna": "c.578G>T",
            "protein": "p.R193L",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 116058,
            "transcript": "NM_058216",
            "gDna": "chr17:g.58703202G>T",
            "cDna": "c.578G>T",
            "protein": "p.R193L",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 116059,
            "transcript": "XM_006722001",
            "gDna": "chr17:g.58703202G>T",
            "cDna": "c.578G>T",
            "protein": "p.R193L",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}